Update on Antioxidant Therapy with Edaravone: Expanding Applications in Neurodegenerative Diseases

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2024 Mar 13

PMID 38474192

Authors

Toru Yamashita

Koji Abe

Affiliations

Soon will be listed here.

Abstract

The brain is susceptible to oxidative stress, which is associated with various neurological diseases. Edaravone (MCI-186, 3-methyl-1 pheny-2-pyrazolin-5-one), a free radical scavenger, has promising effects by quenching hydroxyl radicals (∙OH) and inhibiting both ∙OH-dependent and ∙OH-independent lipid peroxidation. Edaravone was initially developed in Japan as a neuroprotective agent for acute cerebral infarction and was later applied clinically to treat amyotrophic lateral sclerosis (ALS), a neurodegenerative disease. There is accumulating evidence for the therapeutic effects of edaravone in a wide range of diseases related to oxidative stress, including ischemic stroke, ALS, Alzheimer's disease, and placental ischemia. These neuroprotective effects have expanded the potential applications of edaravone. Data from experimental animal models support its safety for long-term use, implying broader applications in various neurodegenerative diseases. In this review, we explain the unique characteristics of edaravone, summarize recent findings for specific diseases, and discuss its prospects for future therapeutic applications.

Citing Articles

Edaravone reduces brain injury in hepatic encephalopathy by upregulation of Nrf2/HO-1 and inhibition of NF-κB, iNOS/NO and inflammatory cytokines.

Amirshahrokhi K, Imani M Mol Biol Rep. 2025; 52(1):222.

PMID: 39937373 DOI: 10.1007/s11033-025-10343-3.

Glial Cell Reprogramming in Ischemic Stroke: A Review of Recent Advancements and Translational Challenges.

Gresita A, Hermann D, Boboc I, Doeppner T, Petcu E, Semida G Transl Stroke Res. 2025; .

PMID: 39904845 DOI: 10.1007/s12975-025-01331-7.

Comparative efficacy of neuroprotective agents for improving neurological function and prognosis in acute ischemic stroke: a network meta-analysis.

Wang Y, Li M, Jiang Y, Ji Q Front Neurosci. 2025; 18():1530987.

PMID: 39834702 PMC: 11743486. DOI: 10.3389/fnins.2024.1530987.

Cerebral amyloid angiopathy-related inflammation (CAA-ri): A case report.

Meng Y, Xiao Y, Sun R, Li L, Dong Y Medicine (Baltimore). 2024; 103(51):e41010.

PMID: 39705440 PMC: 11666186. DOI: 10.1097/MD.0000000000041010.

Edaravone's reno-protective effects against chronic heat-stress exposure.

Alquraan L, Alzoubi K, Jaber S, Khabour O, Al-Trad B, Al-Shwaheen A Naunyn Schmiedebergs Arch Pharmacol. 2024; .

PMID: 39625491 DOI: 10.1007/s00210-024-03685-5.

References

Ogasawara K, Inoue T, Kobayashi M, Endo H, Fukuda T, Ogawa A . Pretreatment with the free radical scavenger edaravone prevents cerebral hyperperfusion after carotid endarterectomy. Neurosurgery. 2004; 55(5):1060-7. DOI: 10.1227/01.neu.0000140838.27450.63. View

Abe K, Itoyama Y, Sobue G, Tsuji S, Aoki M, Doyu M . Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler Frontotemporal Degener. 2014; 15(7-8):610-7. PMC: 4266079. DOI: 10.3109/21678421.2014.959024. View

Okada M, Yamashita S, Ueyama H, Ishizaki M, Maeda Y, Ando Y . Long-term effects of edaravone on survival of patients with amyotrophic lateral sclerosis. eNeurologicalSci. 2018; 11:11-14. PMC: 6006910. DOI: 10.1016/j.ensci.2018.05.001. View

Yoshino H, Kimura A . Investigation of the therapeutic effects of edaravone, a free radical scavenger, on amyotrophic lateral sclerosis (Phase II study). Amyotroph Lateral Scler. 2006; 7(4):241-5. DOI: 10.1080/17482960600881870. View

Watanabe T, Egawa M . Effects of an antistroke agent MCl-186 on cerebral arachidonate cascade. J Pharmacol Exp Ther. 1994; 271(3):1624-9. View

KUEHL Jr F, Humes J, Egan R, HAM E, BEVERIDGE G, VAN ARMAN C . Role of prostaglandin endoperoxide PGG2 in inflammatory processes. Nature. 1977; 265(5590):170-3. DOI: 10.1038/265170a0. View

. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995; 333(24):1581-7. DOI: 10.1056/NEJM199512143332401. View

Kawai H, Nakai H, Suga M, Yuki S, Watanabe T, Saito K . Effects of a novel free radical scavenger, MCl-186, on ischemic brain damage in the rat distal middle cerebral artery occlusion model. J Pharmacol Exp Ther. 1997; 281(2):921-7. View

Ueno Y, Zhang N, Miyamoto N, Tanaka R, Hattori N, Urabe T . Edaravone attenuates white matter lesions through endothelial protection in a rat chronic hypoperfusion model. Neuroscience. 2009; 162(2):317-27. DOI: 10.1016/j.neuroscience.2009.04.065. View

10.

Xu J, Wang A, Meng X, Yalkun G, Xu A, Gao Z . Edaravone Dexborneol Versus Edaravone Alone for the Treatment of Acute Ischemic Stroke: A Phase III, Randomized, Double-Blind, Comparative Trial. Stroke. 2021; 52(3):772-780. DOI: 10.1161/STROKEAHA.120.031197. View

11.

Michino T, Tanabe K, Takenaka M, Akamatsu S, Uchida M, Iida M . Edaravone attenuates sustained pial arteriolar vasoconstriction independently of endothelial function after unclamping of the abdominal aorta in rabbits. Korean J Anesthesiol. 2021; 74(6):531-540. PMC: 8648506. DOI: 10.4097/kja.21155. View

12.

. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017; 16(7):505-512. DOI: 10.1016/S1474-4422(17)30115-1. View

13.

Aoki M, Ogasawara M, Matsubara Y, Narisawa K, Nakamura S, Itoyama Y . Mild ALS in Japan associated with novel SOD mutation. Nat Genet. 1993; 5(4):323-4. DOI: 10.1038/ng1293-323. View

14.

Mead R, Higginbottom A, Allen S, Kirby J, Bennett E, Barber S . S[+] Apomorphine is a CNS penetrating activator of the Nrf2-ARE pathway with activity in mouse and patient fibroblast models of amyotrophic lateral sclerosis. Free Radic Biol Med. 2013; 61:438-52. PMC: 3684770. DOI: 10.1016/j.freeradbiomed.2013.04.018. View

15.

Lees K, Asplund K, Carolei A, Davis S, Diener H, Kaste M . Glycine antagonist (gavestinel) in neuroprotection (GAIN International) in patients with acute stroke: a randomised controlled trial. GAIN International Investigators. Lancet. 2000; 355(9219):1949-54. DOI: 10.1016/s0140-6736(00)02326-6. View

16.

Ohta Y, Nomura E, Shang J, Feng T, Huang Y, Liu X . Enhanced oxidative stress and the treatment by edaravone in mice model of amyotrophic lateral sclerosis. J Neurosci Res. 2018; 97(5):607-619. DOI: 10.1002/jnr.24368. View

17.

Kimura K, Aoki J, Sakamoto Y, Kobayashi K, Sakai K, Inoue T . Administration of edaravone, a free radical scavenger, during t-PA infusion can enhance early recanalization in acute stroke patients--a preliminary study. J Neurol Sci. 2011; 313(1-2):132-6. DOI: 10.1016/j.jns.2011.09.006. View

18.

Yamaguchi T, Sano K, Takakura K, Saito I, Shinohara Y, Asano T . Ebselen in acute ischemic stroke: a placebo-controlled, double-blind clinical trial. Ebselen Study Group. Stroke. 1998; 29(1):12-7. DOI: 10.1161/01.str.29.1.12. View

19.

Coyle J, Puttfarcken P . Oxidative stress, glutamate, and neurodegenerative disorders. Science. 1993; 262(5134):689-95. DOI: 10.1126/science.7901908. View

20.

Clayton A, Shao Q, Paauw N, Giambrone A, Granger J, Warrington J . Postpartum increases in cerebral edema and inflammation in response to placental ischemia during pregnancy. Brain Behav Immun. 2018; 70:376-389. PMC: 5953832. DOI: 10.1016/j.bbi.2018.03.028. View